Patients on long-term haemodialysis receive no major benefit from a higher than standard dialysis dose or high – rather than low – flux dialysis membranes.
This is the conclusion of a trial from the United States led by Dr Garabed Eknoyan from the Baylor College of Medicine, Houston, Texas, for the multicentre Hemodialysis (HEMO) Study.
Until now, the effects of dialysis dose and level of flux of the dialyser membrane on mortality and morbidity among patients on maintenance haemodialysis have been uncertain.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!